Let's Win Pancreatic CancerPancreatic

The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day Two (Part 2/3)

In short

Researchers at a 2021 AACR conference shared early-stage findings on why pancreatic cancer is hard to treat with immunotherapy, how tumor differences between patients affect treatment options, and what new drug combinations and vaccines are being tested in clinical trials. The highlights cover KRAS mutations, immune system barriers, and how large data sets are helping scientists find new targets — all aimed at improving outcomes for pancreatic cancer patients.

  • •Ask your doctor whether your tumor has been tested for KRAS mutations or KRAS wild-type status, since that can affect which therapies may work for you.
  • •If your tumor is KRAS wild-type, ask whether it has mutations in DNA repair genes that might make it sensitive to platinum-based chemotherapy.
  • •A clinical trial testing an mRNA neoantigen vaccine (developed by BioNTech) for pancreatic cancer was fully enrolled as of 2021 — ask your care team about similar vaccine trials that may now be open.
  • •A clinical trial combining a checkpoint inhibitor (nivolumab), chemotherapy, and a synthetic form of vitamin D (paricalcitol) showed early promise in 32 patients and was moving to a larger randomized trial — worth asking your oncologist if this type of combination is relevant to your situation.

Ask anything about this — free, no signup

Instant answers grounded in real guidelines, not the internet.

improved outcomes in mice, which could suggest targeting SREBP as a valid approach for treating pancreatic cancer. Collateral amplification of the KRAS linked gene PTHLH governs pancreatic cancer growth and metastasis and reveals a new therapeutic vulnerability: The gene for parathyroid hormone-related protein (PTHrP) is adjacent to KRAS and often co-amplified with KRAS. According to Jason R. D.

(University of Pennsylvania, Philadelphia), the team has shown that amplification of PTHrP leads to increased metastasis, and that blocking PTHrP in mice either genetically or with an antibody slows metastasis. This finding suggests a new pathway to block metastases in pancreatic cancer patients.

Session 4: Tumor Microenvironment The tumor microenvironment of pancreatic tumors is both heterogeneous and unique and contributes to tumor growth, invasion, metastasis, and immune evasion. The cells in the tumor microenvironment provide the nutrients and protection that allow pancreatic tumors to grow and evade destruction.

These teams are researching approaches to better understand the source of these cells and looking at ways to develop therapies that will disrupt their function and make pancreatic tumors more vulnerable. , University of Michigan Medical School, Ann Arbor. Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1: Post-doctoral research fellow Marie C.

, and a team at Columbia University (New York) are using a novel tumor explant system to look in 3D at how tumors interact with the tumor microenvironment. They are investigating the role of the hedgehog pathway in regulating angiogenesis, and their research has already revealed a potential new target in the Hh pathway to control angiogenesis.

Cancer-associated fibroblasts sustain critical dependency of pancreatic cancer cells on exogenous lipids: Cancer-associated fibroblasts (CAFs) provide nutrients and protection to pancreatic tumors . D. and the Fox Chase Cancer Center team (Philadelphia, Pennsylvania) have developed a novel cell culture model to allow CRISPR screening to identify targets in CAFs.

They have identified a cell surface protein on CAFs (TMEM16) that has clinically available targeted drugs. When this protein is disrupted, cell death occurs. Debate: The KPC Model Has Helped to Advance Pancreatic Cancer Therapy: Agree or Disagree? Kenneth P. D. , is an associate professor in the department of medicine and director of the Oncology Precision Therapeutics and Imaging Core (OPTIC) Shared Resource.

" This effort seeks to treat mice with pancreatic cancer in exactly the same manner that human patients are treated. Associate Professor Phoebe Phillips is a National Health and Medical Research Council Fellow, and leader of the Pancreatic Cancer Translational Research Group at the University of New South Wales, Sydney, Australia. S.

(University of Texas MD Anderson Cancer Center, Houston, Texas), centered on the utility of the KPC mouse in today’s research environment. The KPC mouse has proven itself time and again in “advancing promising biology-based regimens to the clinic and of dissuading the further clinical development of ineffective regimens,” Dr. Olive said. ” On that note, we will leave you to decide.

Stay tuned to Let’s Win for more in-depth coverage of several presentations from this two-day event. And don't forget to read the highlights from Day One .

Highlights

from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.

Follow-up and Monitoring Managing Long-term Side Effects Emotional and Psychological Support Secondary Health Risks Lifestyle Changes On Day Two, the American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer continued its close look at the latest in pancreatic cancer research. This time the focus was on metabolism and RAS signaling, the tumor microenvironment, and the great mouse debate.

Here are the highlights from Day Two. Using an Integrative Molecular Epidemiology Approach to Battle Pancreatic Cancer in the Era of Precision Medicine: Hope Is on the Horizon Precision medicine takes into account individual variability in genes, environment, and lifestyle, allowing doctors to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.

Pancreatic cancer is a heterogeneous disease, and tailoring treatment to an individual is a high-priority goal. D. (University of North Carolina, Chapel Hill). Jennifer B. D. , of the Moffitt Cancer Center in Tampa, Florida, spoke about how precision medicine may be of benefit to pancreatic cancer patients.

One key is to use an integrative molecular epidemiology approach to better understand who is at risk for progression from pancreatic cysts to pancreatic cancer. And it is also vital to understand the racial disparities in pancreatic cancer. Integrative molecular epidemiology is about bringing together epidemiology, data science, and basic science to better understand disease.

Using clinical and basic data, scientists are developing clinical decision tools to aid in IPMN stratification, for example. IPMN is an acronym for intraductal papillary mucinous neoplasm. It’s a type of cyst found in the pancreas. These cysts are benign; however, in a minority of cases an IPMN can develop into a malignant tumor.

These IPMNs can be assigned risk by using a combination of miRNA biomarkers detected in the blood, radiomics data, and genomics information. This approach is currently being developed under the Florida Pancreas Collaborative. Pancreatic cancer racial disparities in Florida mimic the rest of the country, with higher incidence and worse outcomes among African Americans.

Currently, the Florida Pancreas Collaborative has expanded to 15 sites, including academic sites and community hospitals. The group is studying a patient cohort of 500 participants across all 15 sites and assembling clinical data and biosamples to help uncover the drivers of racial disparities. The cohort is 12 percent Black, 16 percent Hispanic, and 72 percent non-Hispanic White.

The team is also beginning to use the biobank to ask questions about why cachexia impacts African American patients more severely and what can be done to improve treatment. Session 3: Metabolism and RAS Signaling Pancreatic cancer’s biology is unique. The malignant cells of pancreatic cancer are able to alter the metabolism, finding ways to survive and spread in nutrient-poor conditions.

Scientists are studying the metabolism of pancreatic cancer to better understand this biology with a goal of identifying new potential therapeutic targets to slow pancreatic cancer growth and metastasis. The session was moderated by Andrew M. D. , University of California San Diego, La Jolla. D.

, Sanford Burnham Prebys Medical Discovery Institute (San Diego, California) and his team are studying pancreatic cancer cells and their uniquely high requirement for the amino acid glutamate. By living in a glutamate-poor environment, these cells undergo metabolic stress which can lead to epithelial to mesenchymal transition (EMT)—the first step in becoming metastatic.

The team is unravelling the pathway linking metabolic stress and EMT and finding new therapeutic targets. D. candidate Laura Leonhardt (University of California San Francisco) spoke about understanding the role of specific epigenetic changes that enable pancreatic cancer initiation and progression. M. (Johns Hopkins University, Baltimore, Maryland) focused her talk on pancreatic cancer cells’ demand for lipids.

These malignant cells manage to survive despite living in a lipid-poor environment. The research team here is investigating the role of lipid homeostasis pathways, which has already revealed a highly active sterol response pathway (SREBP) necessary for growth.

Using lipid-lowering drugs (statins) and anti-clotting drugs (dipyridamole) could show slowed tumor growth and improved outcomes in mice, which could suggest targeting SREBP as a valid approach for treating pancreatic cancer. According to Jason R. D. This finding suggests a new pathway to block metastases in pancreatic tumor in more than 30 percent of cases.

The problem is they don’t engage with the tumor, which may be caused by a lack of antigen specificity or a lack of instruction as to how to attack the tumor. Another immune cell type, dendritic cells (DCs), may hold a clue. In other cancers, presence of DCs correlates with response to checkpoint inhibitors. DCs are impaired in pancreatic cancer animal models as well as human tumors.

Researchers are investigating approaches to expand and mature DCs in animal models of pancreatic cancer. Treatment with two molecules, Flt3 ligand and CD40 ligand, has synergistic effects that lead to better outcomes in animal models. CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily and Flt3L is a cytokine that primes DC cells.

Currently, a clinical trial is getting underway to test the combination of CD40 (CDX-1140) and Flt3L (CDX-301) in resectable pancreatic cancer patients. Immunotherapy in combination: Erkut H. D. from HonorHealth/TGen (Scottsdale, Arizona) presented data from a clinical trial from the lab of Daniel D. Von Hoff of the Translational Genomics Research Institute (TGen) in Phoenix, Arizona.

This phase II trial testing the combination of nivolumab (N), albumin bound paclitaxel (AP), paricalcitol (P), cisplatin (C),and gemcitabine (G)—(NAPPCG)—looked at the potential of adding a synthetic form of vitamin D (paricalcitol) to a combination of chemotherapy and a checkpoint inhibitor (nivolumab).

That data, which evaluated 32 patients treated with the combination, shows promise, with the majority of the patients showing a response to the treatment. This combination is now being evaluated in a follow-up randomized clinical trial. High quality neoantigens are immunoedited in long-term pancreatic cancer survivors: Luis A. , of Memorial Sloan Kettering Cancer Center, New York, discussed ongoing investigations in the lab of Vinod P. D.

The lab is focused on understanding the role of neoantigens in long-term survivors. The hope is that knowledge will lead to new approaches to induce immunity that will control tumors in all patients. Analysis of long-term survivors identified the features of tumor antigens that are present and recognized in long-term survivors. Engineered antigens will be put into vaccines based on these properties.

That approach is now being investigated in a trial with a neoantigen vaccine. Currently, the trial, using mRNA vaccines developed by BioNTech, is fully enrolled. Data will hopefully be available in 2022. Session 2: Big Data Dr. Yeh moderated the session on big data in healthcare. Big data is a term used to describe massive amounts of information created by the adoption of digital technologies.

Big data approaches are being used to address a number of open questions about pancreatic cancer biology. The hope is to reveal new potential drug targets that would be hard to identify using conventional methods. D. , Weill Cornell Medicine, New York, spoke about the development of a mouse model with mutant KRAS that was treated with cerulein to induce pancreatitis (inflammation).

This allowed the researchers to look at the early changes in the pancreatic acinar cells as they transition towards pancreatic cancer. The good news is they are seeing signals in specific pathways that may be drivers of this transition. Integrative genomic characterization of therapeutic targets for pancreatic cancer: Jimmy A. D.

candidate at Broad Institute of MIT and Harvard, (Cambridge, Massachusetts) is currently working at the Broad Institute/Aguirre lab. He spoke about the integration of large ‘omic data sets to help identify new potential drug targets. The team has identified a number of potential targets, including some on the cell surface that are clinically validated as well as some novel targets.

Ongoing research is now hoping to validate potential targets by looking at heterogeneity of expression and whether these targets change expression with chemotherapeutic treatment. Lung-tropic, liver-averse, primary PDAC tumors are associated with greater peripheral T cell diversity and have a unique, subtype-independent, gene-expression signature that significantly correlates with longer survival: Jason M. D.

, Oregon Health & Science University, Portland, Oregon reported on the ongoing research in the lab of Rosalie C. , that focuses on patients with lung metastases. These patients survive longer than those with liver metastases. The lung cohort has more of a “classical” subtype of pancreatic cancer, but this does not entirely explain survival benefit. The team hopes to define gene expression that drives organ tropism and better survival.

Three key features are emerging: low replication stress (pORG), low EMT (pSUB), and high peripheral TCR diversity. Efforts are underway to find ways to target these features therapeutically. Read the highlights from Day Two to learn more about the latest research. com/letswinpc On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next.

Follow-up and Monitoring Managing Long-term Side Effects Emotional and Psychological Support Secondary Health Risks Lifestyle Changes The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer proves that despite an ongoing pandemic, pancreatic cancer research hasn’t missed a beat.

Research labs across the country, and across the world for that matter, are continuing their varied and novel work in gaining a better understanding of pancreatic cancer. The goal is to translate this knowledge into new approaches to treatment that could benefit more patients. As we do every year, Let’s Win will be bringing you highlights from the two-day event held September 29 and 30, 2021.

We will cover some of this research in more depth in the coming months. This year’s conference co-chairs include Andrew M. D. D. , University of Michigan Medical School (Ann Arbor); Robert H. Phil. D. Lead support is provided by the Lustgarten Foundation and major support is provided by the Pancreatic Cancer Action Network (PanCAN) . Here are some highlights from Day One. D. , of Dana-Farber Cancer Institute, Boston, Massachusetts.

In pancreatic cancer, no two tumors are alike. Aguirre reviewed data about the heterogeneity, or differences, of pancreatic cancer tumors and how a better understanding of particular features of a patient’s tumor can lead to different therapeutic options. With thousands of pancreatic cancer genomes published, researchers now know more about the drivers of pancreatic cancer and the frequency of those drivers.

For example, the majority of pancreatic cancers—more than 90 percent—have KRAS mutations. The rare tumors that do not contain KRAS mutations, so-called KRAS wild-type (WT) tumors, often have other actionable mutations, meaning doctors can target those mutations with certain therapies. For example, many KRAS WT tumors contain germline or somatic mutations in DNA repair mechanisms and are sensitive to platinum-based therapies.

” Unlike the “basal-like” type, ongoing studies show the “classical” type of pancreatic cancer has an overall better prognosis and tends to be more sensitive to chemotherapy. But further research shows these two types are also very plastic, meaning that each type can contain cells with both features. In other words, a “classical” type can contain some “basal-like” cells and vice versa. Plus, these types can change, or transition.

Research is continuing using single-cell sequencing of biopsies and organoids to better understand these subtypes and how best to treat them. Efforts to target KRAS, the so-called “undruggable” mutation, are ongoing and showing promise. In fact, there are drugs that can inhibit the KRAS mutants common in lung and colorectal cancer, and new drugs are being generated for the mutations common in pancreatic cancer.

Research in lung and colorectal cancer shows that the KRAS drugs are effective initially, but these tumors acquire resistance to treatment quickly. Scientists are working to better understand the pathways driving this resistance and running screens to better identify new targets in combination with KRAS in pancreatic cancer.

Session 1: Immunotherapy Translation In Progress Immunotherapy has dramatically changed treatment for some cancers like melanoma and lung cancer. Researchers want to make immunotherapy a reality for pancreatic cancer too. The good news is a better understanding of the immunology of pancreatic cancer is advancing to the point where knowledge of this underlying biology is being translated into new approaches in the clinic.

The following presentations highlight different approaches that may help the immune system to destroy pancreatic cancer tumors. Dendritic cell cornerstone of tumor immunity in PDAC: Checkpoint inhibitors work by releasing a natural brake on your immune system so that immune cells called T cells recognize and attack tumors. But in pancreatic cancer, there is a lack of response to T cell checkpoint inhibitors.

Researchers are trying to figure out why. According to David G. D. (Washington University School of Medicine, St. Louis, Missouri), the glitch isn’t caused by a lack of T cells, since these immune cells infiltrate the tumor in more than 30 percent of cases. Treatment with two molecules, Flt3 ligand and CD40 ligand, has lung metastases.

Highlights

Want to learn more about your specific case?

Upload your medical records and ask Navis questions tailored to your diagnosis.